|
WDR35 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
8.61689608555594E-11 |
| Normal-vs-Stage3 |
2.22044604925031E-15 |
| Normal-vs-Stage4 |
1.45439216225896E-14 |
| Stage1-vs-Stage2 |
5.062800E-01 |
| Stage1-vs-Stage3 |
1.730600E-01 |
| Stage1-vs-Stage4 |
1.256170E-02 |
| Stage2-vs-Stage3 |
7.420600E-01 |
| Stage2-vs-Stage4 |
2.634800E-01 |
| Stage3-vs-Stage4 |
3.511200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.223400E-04 |
| Normal-vs-Asian |
6.1612004387257E-10 |
| Caucasian-vs-AfricanAmerican |
3.930400E-02 |
| Caucasian-vs-Asian |
3.216800E-01 |
| AfricanAmerican-vs-Asian |
2.232600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.09801057135428E-13 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.886020E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62658775337832E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
2.00917060766415E-12 |
| Normal-vs-Age(81-100Yrs) |
1.600060E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.811800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.730600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.014600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.705200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.088000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.788600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.171700E-02 |
| Classical-VS-Follicular |
1.226450E-01 |
| Classical-VS-Other |
4.349200E-01 |
| Classical-VS-Normal |
1.06360031892905E-10 |
| Tall-VS-Follicular |
2.034000E-01 |
| Tall-VS-Other |
6.713200E-01 |
| Tall-VS-Normal |
1.36635147640618E-12 |
| Follicular-VS-Other |
8.263800E-01 |
| Follicular-VS-Normal |
3.00626190608E-12 |
| Other-VS-Normal |
8.643800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
4.71860328588036E-11 |
| N0-vs-N1 |
8.369000E-01 |
|
|
